Protection by flavonoids against anthracycline cardiotoxicity: from chemistry to clinical trials
Tóm tắt
Cardiotoxic side-effects of doxorubicin limit the clinical use of this anti-cancer agent. Iron chelators have been studied as protectors against doxorubicin-induced cardiotoxicity. These iron chelators do not provide optimal protection and have certain drawbacks. We therefore looked for new protectors and decided that these new compounds should combine iron chelating and antioxidant activity. Flavonoids appeared to possess those combined iron chelating and antioxidant properties. Quantum chemical evaluation of radical stabilization and determination of physico-chemical properties of a series of flavonoids brought our attention to the semi-synthetic flavonoid 7-monohydroxyetylrutoside (monoHER). Both in vitro (using an electrically paced mouse left atrium model) and in vivo (using a mouse ECG telemetry model) experiments corroborated the protective effect of monoHER. MonoHER also showed anti-inflammatory properties. A subsequent clinical phase I study showed that an i.v. dose of 1,500 mg/m2 is a feasible and safe dose to be evaluated in a phase II study to investigate the protective properties of monoHER against doxorubicin-induced cardiotoxicity in cancer patients.
Tài liệu tham khảo
Goeptar, A. R., Te Koppele, J. M., Lamme, E. K., Piqué, J. M., & Vermeulen, N. P. E. (1993). Cytochrome P450 2B1-mediated one-electron reduction of adriamycin: A study with rat liver microsomes and purified enzymes. Molecular Pharmacology, 44, 1267–1277.
Creighton, A. M., Hellmann, K., & Whitecross, S. (1969). Antitumour activity in a series of bisketopiperazines. Nature, 222, 384–385.
Holcenberg, J. S., Tutsch, K. D., Earhart, R. H., Ungerleider, R. S., Kamen, B. A., Pratt, C. B., Gribble, T. J., & Glaubiger, D. L. (1986). Phase I study of ICRF-187 in paediatric cancer patients and comparison of its pharmacokinetics in children and adults. Cancer Treatment Reports, 70, 703–709.
Decorti, G., Bartoli Klugmann, F., Mallardi, F., Klugmann, S., Benussi, B., Grill, V., & Baldini, L. (1983). Effects of ICRF 159 on adriamycin-induced cardiomyopathy in rats. Cancer Letters, 19, 77–83.
Perkins, W. E., Schroeder, R. L., Carrano, R. A., & Imondi, A. R. (1982). Effect of ICRF-187 on doxorubicin-induced myocardial effects in the mouse and guinea pig. British Journal of Cancer, 46, 662–667.
van Acker, S. A. B. E., van den Berg, D.-J., Tromp, M. N. J. L., Griffioen, D. H., van Bennekom, W. P., van der Vijgh, W. J. F., & Bast, A. (1996a). Structural aspects of antioxidant activity of flavonoids. Free Radical Biology & Medicine, 20, 331–342.
van Acker, S. A. B. E., van den Berg, D.-J., Tromp, M. N. J. L., Griffioen, D. H., van Bennekom, W. P., van der Vijgh, W. J. F., & Bast, A. (1996b). A quantum chemical explanation for the antioxidant activity of flavonoids. Chemical Research in Toxicology, 9, 1305–1312.
van Acker, S. A. B. E., Plemper van Balen, G., van den Berg, D.-J., Bast, A., & van der Vijgh, W. J. F. (1998). Influence of iron chelation on the antioxidant activity of flavonoids. Biochemical Pharmacolgy, 56, 935–943.
van Acker, S. A. B. E., Voest, E. E., Beems, D. B., Madhuizen, H. T., de Jong, J., Bast, A., & van der Vijgh, W. J. F. (1993). Cardioprotective properties of O-(beta-hydroxyethyl)-rutosides in doxorubicin-pretreated BALB/c mice. Cancer Research, 53, 4603–4607.
Voest, E. E., van Acker, S. A. B. E., van der Vijgh, W. J. F., van Asbeck, B. S., & Bast, A. (1994). Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity. Journal of Molecular and Cellular Cardiology, 26, 1179–1185.
Hüsken, B. C. P., de Jong, J., Beekman, B., Onderwater, R. C. A., van der Vijgh, W. J. F., & Bast, A. (1995). Modulation of the in vitro cardiotoxicity of doxorubicin by flavonoids. Cancer Chemotherapy and Pharmacology, 37, 55–62.
van Acker, S. A. B. E., Kramer, K., Grimbergen, J. A., van den Berg, D.-J., van der Vijgh, W. J. F., & Bast, A. (1995). Monohydroxyethylrutoside as protector against chronic doxorubicin-induced cardiotoxicity. British Journal of Pharmacology, 115, 1260–1264.
van Acker, S. A. B. E., Boven, E., Kuiper, K., van den Berg, D.-J., Grimbergen, J. A., Kramer, K., Bast, A., & van der Vijgh, W. J. F. (1997). Monohydroxyethylrutoside, a dose dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin. Clinical Cancer Research, 3, 1747–1754.
Kaiserova, H., den Hartog, G. J. M., Simunek, T., Schoterova, L., Kvasnickova, E., & Bast, A. (2006). Iron is not involved in oxidative stress-mediated cytotoxicity of doxorubicin and bleomycin. British Journal of Pharmacology, 149, 920–930.
Abou El Hassan, M. A. I., Verheul, H. M. W., Jorna, A. S., Schalkwijk, C., van Bezu, J., van der Vijgh, W. J. F., & Bast, A. (2003). The new cardioprotector monohydroxyethylrutoside protects against doxorubicin-induced inflammatory effects in vitro. British Journal Cancer, 89, 357–362.
de Celle, T., Heeringa, P., Strzelecka, A. E., Bast, A., Smits, J. F., & Janssen, B. J. (2004). Sustained protective effects of 7-monohydroxyethylrutoside in an in vivo model of cardiac ischemia-reperfusion. European Journal of Pharmacology, 494, 205–212.
Willems, A. M., Bruynzeel, A. M., Kedde, M. A., van Groeningen, C. J., Bast, A., & van der Vijgh, W. J. F. (2006). A phase I study of monohydroxyethylrutoside in healthy volunteers. Cancer Chemotherapy and Pharmacology, 57, 678–684.